TECH - バイオテクネ (Bio-Techne Corp) バイオテクネ

 TECHのチャート


 TECHの企業情報

symbol TECH
会社名 Bio-Techne Corp (バイオテクネ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイオ・テクネ(Bio-Techne Corp)(旧名:TECHNE Corporation)はバイオテクノロジー製品、血液学校正器及びコントロールの開発・生産・販売に従事する企業である。同社は完全子会社Research and Diagnostic Systems Inc.、Boston Biochem Inc及びBiosPacific Inc.を通して事業を展開している。同社はバイオテクノロジー事業及び血液学事業の2つの部門を通して運営する。バイオテクノロジー事業部門は世界中においてバイオテクノロジーの研究・診断製品を開発・製造・販売する。血液学事業は研究・開発システム血液学区分により構成され、世界中において血液学コントロール・校正器を開発・製造する。   バイオテクネは米国のバイオテクノロジ―製品メ―カ―。バイオテクノロジ―製品および臨床診断管理製品を開発、製造、販売する。バイオテクノロジ―部門はバイオテクノロジ―研究と診断製品の開発、製造、販売を手掛ける。診断管理製品部門は臨床市場向けにコントロ―ル試薬および測定器を提供。   Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014.
本社所在地 614 McKinley Place N.E. Minneapolis MN 55413 USA
代表者氏名 Robert V. Baumgartner Robert V. Baumgartner
代表者役職名 Independent Chairman of the Board
電話番号 +1 612-379-8854
設立年月日 1976年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 2000人
url www.bio-techne.com
nasdaq_url https://www.nasdaq.com/symbol/tech
adr_tso
EBITDA EBITDA(百万ドル) 222.61500
終値(lastsale) 189.31
時価総額(marketcap) 7148019040.25
時価総額 時価総額(百万ドル) 7118.567
売上高 売上高(百万ドル) 642.99300
企業価値(EV) 企業価値(EV)(百万ドル) 7275.813
当期純利益 当期純利益(百万ドル) 92.94900
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 BIO-TECHNE Corp revenues increased 14% to $643M. Net income before extraordinary items increased 22% to $93M. Revenues reflect Biotechnology segment increase of 16% to $421.5M Protein Platforms segment increase of 22% to $111.9M Diagnostics segment increase of 3% to $110.1M United States segment increase of 11% to $346.3M Europe_Middle East segment increase of 19% to $148.6M.

 TECHのテクニカル分析


 TECHのニュース

   Liquid Biopsy Market 2022 Top Leading Players, Recent Developments, Opportunities, Size, Revenue, Sales, Regional Analysis, Business Strategies, Challenges, Types, Applications  2022/04/07 06:17:27 Benzinga
Pune, April 07, 2022 (GLOBE NEWSWIRE) -- Global Liquid Biopsy Market report is expert study that can deliver you with an elaborate analysis of the Liquid Biopsy. The report covers information about top players, projected size of the market, data and figures to update about where opportunities are in the market, competitor analysis and vendor information. Also, it offers a complete analysis of the key market dynamics, with growth drivers, challenges, restraints, opportunities and trends. Furthermore, receive exact details and statistics associated to Liquid Biopsy market and its key factors such as revenue, growth, compound annual growth, year-over-year developments, consumption, and production. The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years.
   Sources: Louisiana Tech expected to hire Hester  2022/03/28 21:50:46 Kwhen Finance
   GreenPath Financial Wellness Announces Board Transition  2022/03/23 15:00:00 Kwhen Finance
   Bio-Techne, Thermo Fisher ink contract to develop/sell kidney transplant rejection test  2022/02/22 13:44:31 Seeking Alpha
Bio-Techne (TECH) signed an agreement with Thermo Fisher Scientific (TMO) to exclusively complete the development and commercialize ExoTRU kidney transplant rejection test developed
   BIO-TECHNE TO PRESENT AT THE 11th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE  2022/02/11 12:00:00 PR Newswire
MINNEAPOLIS, Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST. A live…
   Bio-Techne, Thermo Fisher ink contract to develop/sell kidney transplant rejection test  2022/02/22 13:44:31 Seeking Alpha
Bio-Techne (TECH) signed an agreement with Thermo Fisher Scientific (TMO) to exclusively complete the development and commercialize ExoTRU kidney transplant rejection test developed
   BIO-TECHNE TO PRESENT AT THE 11th ANNUAL SVB LEERINK GLOBAL HEALTHCARE CONFERENCE  2022/02/11 12:00:00 PR Newswire
MINNEAPOLIS, Feb. 11, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST. A live…
   Did The Smart Money Get Bio-Techne Corporation (TECH) Right?  2022/02/07 17:14:16 Insider Monkey
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors…
   Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q2 2022 Results - Earnings Call Transcript  2022/02/01 19:38:12 Seeking Alpha
   S&P Levels To Watch As "Fed Speakers Lunge Around Like ''Short Gamma'' Traders"  2022/02/01 16:53:09 Zero Hedge
S&P Levels To Watch As "Fed Speakers Lunge Around Like ''Short Gamma'' Traders" After the epic melt-up into month-end, during which the world and their pet rabbit was forced to cover or roll any and all downside hedges, the question now is what happens next? Ahead of the now ''common knowledge'' that Friday''s payrolls print is going to be a disaster (potentially a negative number) - and reassurances from various ''experts'' that this will be ''transitory'', Nomura''s Charlie McElligott comments that Fed Speakers are lunging around like short Gamma traders: The Bostic 50bps mis-headline-ing episode over the wknd having to then be walked back yesterday - followed by Feds Daly also then having to clarify early comments made just hours before yesterday as well - are stark reminders that the months ahead are going to get ugly w.r.t. Fed speak being over-interpreted as forward guidance, when in reality, their commentary is merely a reflection of extremely high inflation - and wages - convexity month-to-month.
   Raymond James Trust N.A. Cuts Position in Bio-Techne Co. (NASDAQ:TECH)  2021/12/04 13:12:42 Dakota Financial News
Raymond James Trust N.A. lessened its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 9.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,437 shares of the biotechnology companys stock after selling 155 shares during the quarter. Raymond James Trust N.A.s []
   Legacy Capital Partners Inc. Buys New Shares in Bio-Techne Co. (NASDAQ:TECH)  2021/12/01 13:34:42 Transcript Daily
Legacy Capital Partners Inc. bought a new stake in Bio-Techne Co. (NASDAQ:TECH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 415 shares of the biotechnology companys stock, valued at approximately $201,000. Other hedge funds and other institutional investors also recently []
   Ritholtz Wealth Management Takes $245,000 Position in Bio-Techne Co. (NASDAQ:TECH)  2021/12/01 11:36:45 Dakota Financial News
Ritholtz Wealth Management acquired a new stake in Bio-Techne Co. (NASDAQ:TECH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 505 shares of the biotechnology companys stock, valued at approximately $245,000. A number of other institutional investors have also made changes []
   Zacks: Analysts Expect Bio-Techne Co. (NASDAQ:TECH) Will Announce Quarterly Sales of $267.04 Million  2021/11/28 18:00:42 Dakota Financial News
Wall Street analysts expect Bio-Techne Co. (NASDAQ:TECH) to announce $267.04 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Bio-Technes earnings, with the highest sales estimate coming in at $268.70 million and the lowest estimate coming in at $263.81 million. Bio-Techne posted sales of $224.25 million during []
   Zacks: Analysts Anticipate Bio-Techne Co. (NASDAQ:TECH) to Announce $1.82 Earnings Per Share  2021/11/26 16:30:41 Dakota Financial News
Equities research analysts expect Bio-Techne Co. (NASDAQ:TECH) to post $1.82 earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Bio-Technes earnings. The highest EPS estimate is $1.87 and the lowest is $1.78. Bio-Techne reported earnings of $1.62 per share in the same quarter last year, which []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオテクネ TECH Bio-Techne Corp)

 twitter  (公式ツイッターやCEOツイッターなど)